Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 3
2017 9
2018 30
2019 35
2020 43
2021 75
2022 140
2023 220
2024 321

Text availability

Article attribute

Article type

Publication date

Search Results

784 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Rubino D, et al. JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224. JAMA. 2021. PMID: 33755728 Free PMC article. Clinical Trial.
IMPORTANCE: The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or obesity is unknown. ...CONCLUSIONS AND RELEVANCE: Among adults with overweight …
IMPORTANCE: The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on wei …
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Tan HC, Dampil OA, Marquez MM. Tan HC, et al. J ASEAN Fed Endocr Soc. 2022;37(2):65-72. doi: 10.15605/jafes.037.02.14. Epub 2022 Aug 23. J ASEAN Fed Endocr Soc. 2022. PMID: 36578889 Free PMC article. Review.
BACKGROUND: The weight loss benefit of semaglutide in patients with diabetes is well-documented, but its clinical utility in treating obesity among patients without diabetes is less described. ...CONCLUSION: Among individuals with obesity without type 2 diabe …
BACKGROUND: The weight loss benefit of semaglutide in patients with diabetes is well-documented, but its clinical utili …
Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G, Krauthamer M, Bjalme-Evans M. Singh G, et al. J Investig Med. 2022 Jan;70(1):5-13. doi: 10.1136/jim-2021-001952. Epub 2021 Oct 27. J Investig Med. 2022. PMID: 34706925 Free PMC article. Review.
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antidiabetic medications that have shown promise in encouraging glycemic control and promoting weight loss in patients with or without type 2 diabetes. This literature review summarizes and discusses t …
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antidiabetic medications that have shown promise in encouraging glycemic co …
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH. O'Neil PM, et al. Lancet. 2018 Aug 25;392(10148):637-649. doi: 10.1016/S0140-6736(18)31773-2. Epub 2018 Aug 16. Lancet. 2018. PMID: 30122305 Clinical Trial.
BACKGROUND: Obesity is a major public health issue, and new pharmaceuticals for weight management are needed. Therefore, we evaluated the efficacy and safety of the glucagon-like peptide-1 (GLP-1) analogue semaglutide in comparison with liraglutide and a placebo in …
BACKGROUND: Obesity is a major public health issue, and new pharmaceuticals for weight management are needed. Therefore, we evaluated …
Semaglutide (Ozempic) for weight loss.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2021 Apr 5;63(1621):53-54. Med Lett Drugs Ther. 2021. PMID: 33830968 No abstract available.
As Ozempic's Popularity Soars, Here's What to Know About Semaglutide and Weight Loss.
Suran M. Suran M. JAMA. 2023 May 16;329(19):1627-1629. doi: 10.1001/jama.2023.2438. JAMA. 2023. PMID: 37099334
This Medical News article discusses chronic weight management with semaglutide, sold under the brand names Ozempic and Wegovy....
This Medical News article discusses chronic weight management with semaglutide, sold under the brand names Ozempic and Wegovy. …
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators. Rubino DM, et al. JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619. JAMA. 2022. PMID: 35015037 Free PMC article. Clinical Trial.
MAIN OUTCOMES AND MEASURES: The primary end point was percentage change in body weight, and confirmatory secondary end points were achievement of 10% or more, 15% or more, and 20% or more weight loss, assessed for semaglutide vs liraglutide at week 68. …
MAIN OUTCOMES AND MEASURES: The primary end point was percentage change in body weight, and confirmatory secondary end points were ac …
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity.
Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A. Ghusn W, et al. JAMA Netw Open. 2022 Sep 1;5(9):e2231982. doi: 10.1001/jamanetworkopen.2022.31982. JAMA Netw Open. 2022. PMID: 36121652 Free PMC article. Clinical Trial.
OBJECTIVE: To study weight loss outcomes associated with semaglutide treatment at doses used in randomized clinical trials for patients with overweight or obesity. ...Of the 102 patients who were followed up at 6 months, 89 (87.3%) achieved weight l …
OBJECTIVE: To study weight loss outcomes associated with semaglutide treatment at doses used in randomized clinical tri …
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. N Engl J Med. 2021. PMID: 33567185 Clinical Trial.
Whether adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 mg as an adjunct to lifestyle intervention has not been confirmed. ...CONCLUSIONS: In participants with overweight or obesity, 2.4 mg of semaglutide once …
Whether adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 mg as an adjunct to l …
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. Diabetes Obes Metab. 2022. PMID: 35441470 Free PMC article. Clinical Trial.
RESULTS: Extension analyses included 327 participants. From week 0 to week 68, mean weight loss was 17.3% (SD: 9.3%) with semaglutide and 2.0% (SD: 6.1%) with placebo. Following treatment withdrawal, semaglutide and placebo participants regained 11.6 ( …
RESULTS: Extension analyses included 327 participants. From week 0 to week 68, mean weight loss was 17.3% (SD: 9.3%) with s …
784 results

Searches related to "semaglutide weight loss"